A PYMNTS Company

2025: Reverse-Payment Settlements Unleashed

BY | December 16, 2010

Dec 16, 2010 The year is 2025. For the past two decades, brand-name drug companies have settled infringement lawsuits with generic firms by paying them to drop their patent challenges.…

Dec 16, 2010

The year is 2025. For the past two decades, brand-name drug companies have settled infringement lawsuits with generic firms by paying them to drop their patent challenges. Early in the 21st century, courts had explained that this was the natural state of affairs. By 2025, this is true many times over.

This outcome traces back to 2005, when the Schering and Tamoxifen appellate courts upheld reverse-payment agreements. In the five years before that, drug firms had been more careful.

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 98.80.143.34

Please verify email or join us to access premium content!